AstraZeneca's patent on asthma drug invalidated by U.S. court
February 15, 2015 at 19:37 PM EST
NEW YORK, Feb 15 (Reuters) - A U.S. federal judge ruled late on Friday that AstraZeneca PLC's patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, cheaper generic version.
